By doing so, around 80 percent of Canadians over the age of 16 will receive a single dose by the end of June with the expected supply of Pfizer-BioNTech and Moderna vaccines
Companies traditionally pour huge amounts of money and research into drugs and vaccines, for the right to profit from them.
Pfizer-BioNTech and Moderna plan to gradually test their vaccines in younger and younger age groups.
The FDA said J&J's vaccine offers strong protection against serious illness, hospitalisations, and death. The company has said it expects to deliver 20 million doses to the US by the end of March
Either a South Africa variant-specific candidate could be used as a booster or a booster that combines the classic vaccine with the variant-specific will be created.
Johnson & Johnson's single-dose COVID-19 vaccine safe and effective, says FDA paving way for approval
The vaccine was 66.1% effective in preventing moderate to severe disease and appeared safe, the US Food and Drug Administration said on Wednesday
Moderna has delivered about 46 percent of the vaccine stock administered in the US so far, followed by Pfizer-BioNTech.
The shots were all tested differently, and some were allowed to go into use even before they were rigorously tested.
A single-dose vaccine is a big advantage when most countries are struggling to get shots in arms more quickly.
Moderna's vaccine is based on mRNA technology and it 94 percent effective at preventing COVID-19 in people who were given two doses and had no history of the infection.
There is hard evidence that fractional doses and delayed doses have worked when doctors have tried them out of desperation.
Earlier reports said that the AstraZeneca/Oxford vaccine efficacy is as low as eight percent in adults over 65 years.
A YouGov survey this month of roughly 19,000 people in 17 countries and regions showed that most were distrustful of a COVID-19 vaccine made in China
The vaccine, Sputnik V, received a six-month authorisation Wednesday from Hungary’s National Institute of Pharmacy and Nutrition, institute director Matyas Szentivanyi told public television
Logistics at many stages have been worked out keeping this target temperature in mind to meet storage availability.
The new variant carries several peculiar changes to the spike protein when compared to other closely related variants.
US clears Moderna's vaccine against COVID-19; second shot in country's arsenal after Pfizer-BioNTech
The much-needed doses are set to arrive on Monday after the Food and Drug Administration authorized an emergency rollout of the vaccine
The authorisation to use the vaccine developed by Pfizer and BioNTech now clears the way for the deployment of a vaccine that’s expected to play a significant role in the global effort to cub the coronavirus
The country has secured COVID-19 vaccines for 60 million people from pharmaceutical giant Pfizer, and for a further 25 million people from biotech firm Moderna
Moderna says its vaccine 94% effective against COVID-19, asks European and US regulators for emergency use
The US pharma company said it was on track to have about 20 million doses of its vaccine ready to ship in America by 2020-end